Galapagos NV
GLPG
ISIN BE0003818359 / Valor 2130343
Galapagos NV
UMushroom community rating:
About company
Galapagos NV is a Belgium-based clinical-stage biotechnology company that discovers and develops small-molecule medicines primarily for inflammatory and fibrotic diseases. Using internal discovery platforms for target identification and medicinal chemistry, the company advances candidates through preclinical and clinical development and combines an in-house pipeline with strategic partnerships to support later-stage development and commercialization; a notable collaboration with Gilead Sciences has played a central role in the development and commercial strategy for several of its assets. Galapagos is publicly listed (Euronext Brussels and Nasdaq) and focuses on disease-modifying oral therapies, maintaining research operations in Europe and the United States while managing a portfolio that has seen both clinical progress and program setbacks typical of the biotech sector.
Summarized from source with an LLMView SourceSector: HealthcareKey figures
Performance
Volatility
2028 M
Market cap (USD)
55,394
Daily traded volume (Shares)
26.36 / 25.88
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
